Hepatitis Headlines

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.

Hepatitis B Vaccination Prevalence Low in Patients With HIV

Hepatitis B Vaccination Prevalence Low in Patients With HIV

More than one-third of adult US HIV patients miss opportunities to initiate hepatitis B vaccination.

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.

Treatment Regimens and Recommendations for HIV/HCV Coinfection

Treatment Regimens and Recommendations for HIV/HCV Coinfection

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Investigators evaluated whether unfavorable outcomes were prevented once sustained virologic response was achieved in older adults with HCV.

SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.

High Rates of SVR With DAAs in HCV/HIV Coninfection

High Rates of SVR With DAAs in HCV/HIV Coninfection

The advent of direct acting antiviral (DAA) agent therapies has resulted in significant improvements in treatment rates for those with co-infection.

HBV, HCV Increases All-Cause, Liver-Related Mortality in HIV

HBV, HCV Increases All-Cause, Liver-Related Mortality in HIV

Hepatitis B and hepatitis C may increase mortality risks in patients with HIV.

Efficacy of LDV/SOF for Retreatment of Chronic HCV in SOF-Experienced Patients

Efficacy of LDV/SOF for Retreatment of Chronic HCV in SOF-Experienced Patients

The highest SVR12 rates were obtained with 12 weeks of LDV/SOF+RBV in noncirrhotic participants and by extending the duration of LDV/SOF treatment to 24 weeks in cirrhotic individuals.

Sign Up for Free e-newsletters